The FDA issued a complete response letter to Intercept Pharmaceuticals indicating it cannot grant full approval to the company’s supplemental new drug application for Ocaliva as a treatment for primary biliary cholangitis. As Healio previously reported in September, the FDA Gastrointestinal Drug Advisory Committee voted 13 to 1 with no abstentions that the benefits of Ocaliva (obeticholic
PHILADELPHIA — To reflect developments in COPD research and care, the 2025 Global Initiative for Chronic Obstructive Lung Disease report features three new sections and…
Amy Hajari Case, MD, FCCP, has been named chief medical officer of the Pulmonary Fibrosis Foundation, according to a press release.As part of the Pulmonary…
PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented…
Weight loss from weekly semaglutide injections accompanied significant reductions in pain related to knee osteoarthritis, according to data published in The New England Journal of…
Drs Ryan Law and Juan Carlos Bucobo discuss their Technology Status Evaluation Report, “Submucosal injection fluid and tattoo agents” from the November issue…
Why not just invest in one stock and let it ride? That works well if you bet the farm on Apple in 2010 and watched…
Researchers found evidence of artemisinin partial resistance in Ugandan children with complicated malaria, according to data presented at the Annual Meeting of the American Society…
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Diana Do, MD, discusses the PHOTON extension study, which examined…
Prior antibiotic use may be a factor in the rising incidence of colorectal cancer seen in those under 50 years of age (early-onset colorectal cancer…
The American Joint Replacement Registry released its 2024 report on trends in arthroplasty, according to a presenter at the American Association of Hip and Knee…
